Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.
Cisplatin
Docetaxel
NEPC
Prostate cancer
Radiotherapy
mCRPC
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
27
10
2021
accepted:
31
12
2021
pubmed:
13
1
2022
medline:
20
5
2022
entrez:
12
1
2022
Statut:
ppublish
Résumé
Platinum chemotherapy can be considered to treat metastatic castration-resistant prostate cancer (mCRPC) with features of neuroendocrine differentiation. However, platinum compounds are generally only applied after the failure of multiple prior-line treatment options. This study investigated whether acquired resistance against ionizing radiation or docetaxel chemotherapy-two commonly applied treatment modalities in prostate cancer-influences the cisplatin (CDDP) tolerance in mCRPC cell line models. Age-matched parental as well as radio- or docetaxel-resistant DU145 and PC-3 cell lines were treated with CDDP and their sensitivity was assessed by measurements of growth rates, viability, apoptosis, metabolic activity and colony formation ability. The data suggest that docetaxel resistance does not influence CDDP tolerance in all tested docetaxel-resistant cell lines. Radio-resistance was associated with sensitization to CDDP in PC-3, but not in DU145 cells. In general, DU145 cells tolerated higher CDDP concentrations than PC-3 cells regardless of acquired resistances. Furthermore, non-age-matched treatment-naïve PC-3 cells exhibited significantly different CDDP tolerances. Like patients, different mCRPC cell lines exhibit significant variability regarding CDDP tolerance. The presented in vitro data suggest that previous radiation treatment may be associated with a moderate sensitization to CDDP in an isogenic and age-matched setting. Therefore, previous radiotherapy or docetaxel chemotherapy might be no contraindication against initiation of platinum chemotherapy in selected mCRPC patients.
Identifiants
pubmed: 35020044
doi: 10.1007/s00432-022-03914-5
pii: 10.1007/s00432-022-03914-5
pmc: PMC9114061
doi:
Substances chimiques
Docetaxel
15H5577CQD
Platinum
49DFR088MY
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1313-1324Informations de copyright
© 2022. The Author(s).
Références
Int J Legal Med. 1994;107(1):13-20
pubmed: 7999641
Int J Mol Sci. 2020 Jun 03;21(11):
pubmed: 32503307
Cancer Res. 2001 May 15;61(10):4112-21
pubmed: 11358834
Cancer Res. 2015 Apr 1;75(7):1482-94
pubmed: 25670168
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8397-402
pubmed: 10890888
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Cancer Res. 2004 Dec 15;64(24):9209-16
pubmed: 15604294
Eur Urol. 2019 Feb;75(2):242-250
pubmed: 30414698
Am J Pathol. 2012 Dec;181(6):2188-201
pubmed: 23041061
JAMA Netw Open. 2020 Oct 1;3(10):e2021692
pubmed: 33112397
Acta Oncol. 2002;41(7-8):668-74
pubmed: 14651212
Arch Pathol Lab Med. 1988 Nov;112(11):1100-5
pubmed: 2460064
Clin Cancer Res. 2013 Jul 1;19(13):3621-30
pubmed: 23649003
DNA Repair (Amst). 2002 Dec 5;1(12):1003-16
pubmed: 12531010
Cancer Res. 2016 May 1;76(9):2637-51
pubmed: 26984757
Antioxid Redox Signal. 2013 Jun 20;18(18):2420-8
pubmed: 23121537
PLoS One. 2013 May 06;8(5):e63056
pubmed: 23671654
Prostate. 2003 Nov 1;57(3):205-25
pubmed: 14518029
Cancer Res. 1996 Nov 1;56(21):4881-6
pubmed: 8895738
Lancet Oncol. 2019 Oct;20(10):1432-1443
pubmed: 31515154
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Front Oncol. 2013 May 10;3:113
pubmed: 23675572
J Urol. 2007 Sep;178(3 Pt 1):844-8; discussion 848
pubmed: 17631339
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Yeast. 1999 Feb;15(3):205-18
pubmed: 10077187
PLoS Comput Biol. 2019 Nov 4;15(11):e1007460
pubmed: 31682594
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Radiother Oncol. 2015 Apr;115(1):90-5
pubmed: 25770874
Nature. 2007 Jun 21;447(7147):941-50
pubmed: 17581577
Cancer Res. 1995 Dec 15;55(24):6063-70
pubmed: 8521394
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):92-99
pubmed: 29230006
Int J Urol. 2001 Aug;8(8):431-6; discussion 437
pubmed: 11555007
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Mol Oncol. 2017 Mar;11(3):251-265
pubmed: 28133913
Eur Urol. 2016 Jun;69(6):992-5
pubmed: 26724258
Cancer Res. 1996 Jul 1;56(13):3087-90
pubmed: 8674066
Eur Urol. 2019 Jan;75(1):184-192
pubmed: 30340782
Cancer. 2017 Sep 15;123(18):3532-3539
pubmed: 28608931
J Clin Oncol. 2002 Jul 15;20(14):3072-80
pubmed: 12118020
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Ann Oncol. 2011 Nov;22(11):2476-2481
pubmed: 21436186
DNA Repair (Amst). 2015 Nov;35:126-36
pubmed: 26519826
DNA Repair (Amst). 2003 Nov 21;2(11):1199-210
pubmed: 14599742